AI-generated analysis. Always verify with the original filing.
Cadrenal Therapeutics, Inc. issued a press release on March 12, 2026, highlighting pre-clinical research demonstrating the potential of its first-in-class 12-LO product candidate. The press release is furnished as Exhibit 99.1 and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act.
Event Type
Disclosure
Voluntary
Variant
8-K
and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securi
. Other Events. On March 12, 2026, the Company issued a press release highlighting pre-clinical research demonstrating the potential of its first-in-class 12-LO
Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99